University of California, Riverside Assistant Professor of Bioengineering, Jiayu Liao played a pivotal role in the discovery of a small molecule that has been shown to control diabetes in mice and may pave the way to the development of easier treatment for adult-onset diabetes.
This discovery was a collaboration between Liao at UC Riverside's Bourns College of Engineering and a team in the National Center for Drug Screening, Shanghai, which is part of the Chinese Academy of Science.
This key molecule, identified as Boc5, can stimulate insulin function in response to high levels of glucose as well as reduce body weight by 20 percent. The discovery of this molecule that stimulates the production of the intestinal hormone glucagon-like peptide1 (GLP1), which metabolizes glucose, has been an extremely difficult goal for researchers in both academics and the pharmaceutical industry.
Boc5 is the first small molecule activator for Class B GPCRs, which regulate hormones in many human physiological processes and are major targets for pharmaceutical companies. This discovery opened new revenue possibilities to support future research into small molecule interaction with Class B GPCRs in the future.
In the study, Liao and his colleagues were looking for ways to sensitize sugar-metabolizing insulin by stimulating production of GLP1. Synthetic versions of this peptide have proven effective but of short duration so it had been abandoned by drug researchers.
However, after Liao and his colleagues screened a library of more than 48,000 natural and synthetic compounds, they identified a molecule, Boc5, which mimics glucagon-like peptide1 in the blood leading to increases in insulin secretion in laboratory cultured rat pancreatic cells when exposed to high glucose levels. The molecule also worked when administered by injection and orally in experiments with laboratory mice.
Thus Boc5 behaved as full GLP1 mimic, both in the test tube and in the laboratory mice, the researchers reported in an article that appeared in the Jan. 16 edition of the Proceedings of the National Academies of Science titled “A nonpeptidic agonist of glucagon-like peptide 1 receptors with efficacy in diabetic db/db mice.”
The fact that the molecule also lowered appetite and promoted weight loss in mice, holds out the promise it may fuel more exploration of orally available insulin sensitizing drugs that can be used to control diabetes and obesity, the article’s authors wrote.
Ricardo Duran | EurekAlert!
Not of Divided Mind
19.01.2017 | Hertie-Institut für klinische Hirnforschung (HIH)
CRISPR meets single-cell sequencing in new screening method
19.01.2017 | CeMM Forschungszentrum für Molekulare Medizin der Österreichischen Akademie der Wissenschaften
An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...
Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...
Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.
While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...
Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales
Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...
Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.
As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...
19.01.2017 | Event News
10.01.2017 | Event News
09.01.2017 | Event News
19.01.2017 | Earth Sciences
19.01.2017 | Life Sciences
19.01.2017 | Physics and Astronomy